Syphilis diagnosis and treatment during antenatal care: the potential catalytic impact of the dual HIV and syphilis rapid diagnostic test

An estimated 355,000 adverse pregnancy outcomes occur annually due to syphilis, two-thirds of which result in stillbirth or neonatal death. WHO launched the Elimination of Mother-to-Child Transmission of HIV and Syphilis initiative in 2014. However, antenatal syphilis screening and treatment rates remain low across sub-Saharan Africa and parts of Asia, particularly compared with progress made to reduce new HIV infections among infants, which have declined from 270,000 in 2010 to 180,000 in 2017.

Reducing the difference between HIV and syphilis antenatal screening rates would lead to major health gains. For instance, in many countries, up to 95% of women are tested for HIV during antenatal care, but less than 50% are tested for syphilis (figure; appendix).

This gap represents an opportunity to leverage existing antenatal care platforms and technologies to better diagnose and treat maternal syphilis. In 2015, the first dual HIV and syphilis rapid diagnostic test received WHO prequalification on the basis of laboratory assessment, with a second test receiving prequalification status in June, 2019. Field studies show optimal sensitivity (98-100%) and specificity (97-100%) for HIV diagnosis and good sensitivity (89-100%) and specificity (91-100%) for syphilis. Scale up of dual HIV and syphilis rapid diagnostic tests could close the antenatal care syphilis testing gap, providing an opportunity to deliver treatment with injectable benzathine benzylpenicillin during the same visit. Successful implementation of dual HIV and syphilis rapid diagnostic tests in antenatal care would increase syphilis screening rates to match those of HIV in countries such as India where antenatal care syphilis testing rates would increase by 195%, by 119% in Uganda, and by 117% in Nigeria, without affecting HIV-testing rates.

Policies, guidelines, advocacy tools, implementation plans, screening and diagnostic tests, and effective treatment for syphilis are available. So why does this HIV and syphilis antenatal care testing gap exist?

Figure: Testing coverage for HIV and syphilis in pregnant women who visit antenatal care in selected countries (2016-18)

Values are based on syphilis testing rates during antenatal care, HIV testing rates during antenatal care, syphilis prevalence, and HIV prevalence. *Women aged 15-49 years. †Antenatal care attendees.
In 2018, we delivered a series of maternal syphilis workshops with maternal and child health programmes from 25 African countries to identify reasons for the testing gap and opportunities to increase syphilis screening in pregnancy. We identified poor awareness and political will as contributors to low country application of WHO antenatal care syphilis screening guidelines in the region. In this regard, neither national governments nor donors appear to have identified congenital syphilis prevention as a public health priority and few women knew of the effect of syphilis in pregnancy. Funding for the purchase of syphilis test kits and benzathine penicillin primarily comes from national ministries of health budgets, where prioritisation of syphilis control is low. In addition, donor support is minimal.

Congenital syphilis often falls into the fissures between sexually transmitted infections (STI), maternal and child health, and reproductive health programmes, despite WHO advocacy for service integration as part of universal health coverage. For example, some HIV programme managers regarded adding syphilis to prevention of mother-to-child transmission (PMTCT) programmes as complicating the process towards elimination of mother to child transmission of HIV. The level of investment in syphilis diagnosis and treatment is telling when compared with the advocacy, procurement, supply chain, and training systems associated with national HIV programmes. Workshop participants repeatedly described restrictive procurement practices, inefficient distribution of syphilis tests, shortages or stockouts of benzathine penicillin, and missed opportunities to leverage health-care worker training. Integration of maternal syphilis screening and treatment into HIV PMTCT programmes is logical. During the workshops, countries developed national roadmaps for the adoption of new testing algorithms including HIV and syphilis rapid diagnostic tests, forecasting and procurement of test kits, quality assurance, training, and increasing community awareness of syphilis and its association with stillbirth prevention. Subsequently, many countries, with donor and partner support, have commenced activities to identify reliable and predictable sources of additional funding to leverage and supplement existing HIV PMTCT programmes to include dual HIV and syphilis rapid diagnostic tests and ensure benzathine penicillin commodity security.

Countries such as Uganda, Kenya, and Nigeria reported they have already updated their testing algorithm to include the dual HIV and syphilis rapid diagnostic test as the first test for pregnant women attending antenatal care. Several other countries are following suit and workshop participants from remaining countries have indicated high levels of interest in emulating the process. Multiplex testing technologies now offer the opportunity to immediately close the syphilis HIV testing gap among pregnant women. Integrating maternal syphilis screening and treatment into HIV PMTCT programmes is a feasible, so-called best buy scenario for global health investments, is less costly, and results in the fewest adverse pregnancy outcomes compared with other testing algorithms. Dual HIV and syphilis rapid diagnostic tests have shown a high overall diagnostic accuracy for HIV, a high specificity for syphilis diagnosis in antenatal clinic settings and are rated as highly acceptable and feasible.

Using the antenatal care platform for diagnosis of both maternal HIV and syphilis infections using a single rapid diagnostic test is a simple intervention that could rapidly be brought to scale in high-burden countries. This scenario is a test case for WHO’s people-centred integrated service delivery systems. The incremental cost is small, but the potential gains—prevention of stillbirth, preterm birth, neonatal death, and long-term disability of children—are enormous.

*Andrew Storey, Frederic Seghers, Lee Pyne-Mercier, Rosanna W Peeling, Morkor Newman Owiredu, Melanie M Taylor
Maternal and Neonatal Health, Clinton Health Access Initiative, Boston, MA 02127, USA (AS, FS); Maternal, Neonatal and Child Health, Bill & Melinda Gates Foundation, Seattle, WA, USA (LP-M); International Diagnostics Centre, London School of Hygiene & Tropical Medicine, London, UK (RWP); HIV Program (MNO), and Sexually Transmitted Infection Program (MMT), World Health Organization, Geneva, Switzerland; and Division of Sexually Transmitted Disease Prevention, US Centers for Disease Control and Prevention, Atlanta, GA (MMT)
astorey@clintonhealthaccess.org

Copyright © 2019 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article’s original URL.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the World Health Organization. We declare no competing interests.
Korenromp EL, Rowley J, Alonso M, et al. Global burden of maternal and congenital syphilis and associated adverse birth outcomes—estimates for 2016 and progress since 2012. PLoS One 2019;14:e0211720.

2. Gomez G, Kamb M, Newman L, Mark J, Brottet N, Hawkes S. Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. World Health Organization. 2013. https://www.who.int/bulletin/volumes/91/3/12-10623/en/ (accessed May 7, 2019).

3. WHO. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis. World Health Organization. 2019. https://www.who.int/reproductivehealth/publications/emtct-hiv-syphilis/en/ (accessed May 7, 2019).

4. Peeling RW, Mabey D. Celebrating the decline in syphilis in pregnancy: a sobering reminder of what’s left to do. Lancet Glob Health 2016;4:e503–04.

5. UNICEF. Elimination of mother-to-child transmission. United Nations Children’s Fund. 2018. https://data.unicef.org/topic/hivaids/emtct/ (accessed May 7, 2019).

6. UNAIDS. HIV testing among pregnant women. Joint United Nations Programme on HIV/AIDS. 2017. http://aidsinfo.unaids.org/?did=5b55166567e425f81636f6educ=world&t=3&dbt=db&df=4&5tr=1&world&tl=2 (accessed May 7, 2019).

7. WHO. Report on global sexually transmitted infection surveillance 2018. World Health Organization. 2019. https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/ (accessed May 7, 2019).

8. WHO. Report on global sexually transmitted infection surveillance 2015. World Health Organization. 2016. https://www.who.int/reproductivehealth/publications/stis/stis-surveillance-2015/en/ (accessed June 24, 2019).

9. National AIDS Control Organization. National strategic plan for HIV/AIDS and STI, 2017–24. New Delhi: National AIDS Control Organization (under Ministry of Health and Family Welfare), 2017.

10. National Department of Health. The 2015 National Antenatal Sentinel HIV & Syphilis Survey, South Africa. Pretoria: National Department of Health, 2017.

11. National AIDS Control Organization. The national strategy and operational guidelines towards elimination of congenital syphilis. New Delhi: National AIDS Control Organization (under Ministry of Health and Family Welfare and WHO), 2015.

12. WHO. WHO Prequalification of In Vitro Diagnostics Programme: public report number PQDx 0179-012-00. Geneva: World Health Organization, 2015.

13. WHO. WHO Prequalification of In Vitro Diagnostics Programme: public report number PQDx 0164-001-00. Geneva: World Health Organization, 2019.

14. Gliddon HD, Peeling RW, Kamb ML, Taskin I, Wi TE, Taylor MM. A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. Sex Transm Infect 2017;93:33-35.

15. Taylor M, Gliddon H, Nurse-Findlay S, et al. Revisiting strategies to eliminate mother-to-child transmission of syphilis. Lancet Glob Health 2018;6:e26–28.

16. WHO. Prevention of mother-to-child transmission of syphilis (congenital syphilis). World Health Organization. https://www.who.int/reproductivehealth/publications/emtct-hiv-syphilis/en/ (accessed May 7, 2019).

17. WHO. Together on the road to universal health coverage, a call to action. World Health Organization. 2017. https://www.who.int/universal_health_coverage/road-to-uhc/en/ (accessed May 7, 2019).

18. Olugbenga I, Taiwo O, Laverty M, et al. Clinic-based evaluation study of the diagnostic accuracy of a dual rapid test for the screening of HIV and syphilis in pregnant women in Nigeria. PLoS One 2018;13:e0198698.

19. Bristow CC, Larson E, Anderson LJ, Klausner JD. Cost-effectiveness of HIV and syphilis antenatal screening: a modelling study. Sex Transm Infect 2016;92:340–46.

20. WHO. The use of rapid syphilis tests. World Health Organization. 2014. https://www.who.int/reproductivehealth/publications/rtis/TDR_SDI_06_1/en/ (accessed May 7, 2019).

21. John-Stewart G, Peeling RW, Levin C, Garcia PJ, Mabey D, Kinuthia J. Prevention of mother-to-child transmission of HIV and syphilis. In: Holmes KK, Bertozi S, Bloom BR, Jha P, eds. Disease control priorities: major infectious diseases. 3rd edn. Washington, The International Bank for Reconstruction and Development, The World Bank, 2017:133–36.